



March 7, 2023

Dear CAH Community Members,

Adrenas Therapeutics, a BridgeBio affiliate, appreciates your ongoing interest in the investigational gene therapy clinical trial for adults with classic Congenital Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency. The ADventure phase 1/2 clinical trial continues as planned and we are pleased to share an update with you.

In this early phase clinical trial, our goals are to confirm the safety and potential effects of three dose levels (low, middle, high) of the Adrenas' investigational gene therapy, BBP-631, on adrenal-related hormones.

A total of four participants have been dosed in the ADventure clinical trial. Two participants received the investigational gene therapy at the low dose and two participants received it at the middle dose. The investigational gene therapy has been well tolerated by all participants to date, allowing for escalation to the highest dose level to proceed as planned.

As a reminder, the ADventure trial doses one participant at a time with a safety evaluation after each participant is dosed, which is standard practice for early phases of gene therapy trials. A thorough evaluation of the clinical trial safety data is conducted by a panel of independent expert physicians and clinical trial experts who comprise the Data and Safety Monitoring Committee (DSMC). At this early stage of the clinical trial, the approval of the DSMC is required for dosing additional participants at a given dosing level and advancing to higher doses.

We will soon begin dosing participants at the highest dose. Adrenas will continue to collect and review all data to guide our understanding of the potential impact of BBP-631 on the adrenal-related hormones in people living with CAH. We aim to have a more complete understanding by the second half of 2023, and we will update the community at that time.

Adrenas Therapeutics is grateful for the ongoing collaboration with the community and advocacy organizations as we work together to advance meaningful treatment options for people and families affected by CAH.

Sincerely,

The Adrenas Therapeutics Team

Current criteria for trial participation:

- Adults 18 years of age and older
- Diagnosed with classic CAH (simple-virilizing or salt-wasting)
- Managing CAH with glucocorticoids daily (e.g., hydrocortisone, prednisone, methylprednisolone, or dexamethasone)

For information visit <http://cahgenetherapy.com> and <https://clinicaltrials.gov/ct2/show/NCT04783181>